Quantcast
Home > Quotes > EARS
EARS

Auris Medical Holding AG Common Shares (EARS) Quote & Summary Data

$0.2792
*  
0.0195
7.51%
Get EARS Alerts
*Delayed - data as of Aug. 14, 2018  -  Find a broker to begin trading EARS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EARS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 0.28 / $ 0.26
Share Volume
504,795
50 Day Avg. Daily Volume
620,132
Previous Close
$ 0.2597
52 Week High / Low
$ 9.50 / $ 0.25
Market Cap
1,707,975
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.36

Intraday Chart

Shares Traded

Share Volume:
504,795
50 Day Avg. Daily Volume:
620,132

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -4.03

Trading Range

The current last sale of $0.2792 is 11.68% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.28 $ 9.50
 Low: $ 0.26 $ 0.25

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. We have two lead clinical-stage product candidates, (i) Keyzilen┬« (AM-101), which is being developed for the treatment of acute inner ear tinnitus and (ii) AM-111, being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being developed for the treatment of vestibular disorders. In addition, we are pursuing early stage projects for the treatment of tinnitus. Our product candidates Keyzilen┬« and AM-111 are injected under local anesthesia into the middle ear by a technique called intratympanic injection. Once injected into the middle ear, the active substance, which is formulated in a biocompatible gel, diffuses into the inner ear.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.27
Open Date:
Aug. 14, 2018
Close Price:
$ 0.2774
Close Date:
Aug. 14, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info